Stocktoria
Xilio Therapeutics, Inc. XLO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-10-22
Chart by TradingView
4/9
Piotroski F — financial health
-6.58
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $43.8M | $6.3M | — | — | — |
| Operating income | -$42.0M | -$60.6M | -$79.1M | -$89.1M | -$75.0M |
| Net income | -$35.0M | -$58.2M | -$76.4M | -$88.2M | -$75.8M |
| Operating cash flow | -$5.0M | -$18.4M | -$68.6M | -$75.7M | -$80.8M |
| Free cash flow | -$5.5M | -$18.4M | -$69.1M | -$77.6M | -$81.9M |
| Total assets | $154.7M | $71.1M | $60.9M | $139.2M | $218.1M |
| Total liabilities | $119.4M | $53.5M | $24.1M | $33.5M | $32.6M |
| Shareholders' equity | $35.3M | $17.6M | $36.8M | $105.6M | $185.4M |
| Ratios | |||||
| Operating margin | -95.9% | -954.9% | — | — | — |
| Net margin | -80.1% | -918.0% | — | — | — |
| FCF margin | -12.6% | -290.3% | — | — | — |
| Return on assets | -22.6% | -81.9% | -125.4% | -63.4% | -34.8% |
| Return on equity | -99.3% | -331.0% | -207.5% | -83.5% | -40.9% |
| Current ratio | 2.58 | 2.21 | 3.02 | 5.89 | 15.85 |
| Revenue growth | 589.9% | — | — | — | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 49,566 | $416,850 |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -6.58 (distress)
- Working capital / assets 0.574
- Retained earnings / assets -2.707
- EBIT / assets -0.271
- Equity / liabilities 0.295
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001840233 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.